PCSK9i

Low Lipoprotein(a) Levels Linked to Higher Diabetes Risk

This entry was posted in Cardiovascular Diseases and tagged Diabetes Mellitus Lipoprotein(a) PCSK9i Risk on

An analysis from the FOURIER trial found that among patients with established atherosclerotic cardiovascular disease, lower lipoprotein(a) [Lp(a)] concentrations were associated with a higher prevalence of diabetes at baseline and a greater risk of developing diabetes during follow-up, while showing no increased risk of most other major adverse safety outcomes. […]

Evolocumab Reduces First Major Cardiovascular Events in High-Risk Patients Without Known Significant Atherosclerosis

This entry was posted in Cardiovascular Diseases and tagged CVD PCSK9i Primary Prevention on

In high-risk patients with diabetes but no known significant atherosclerosis, treatment with evolocumab significantly reduced the risk of a first major cardiovascular event compared with placebo when added to statin therapy. This prespecified subgroup analysis of the VESALIUS-CV randomized, double-blind, placebo-controlled trial included 3,655 participants from 774 sites across 33 […]